Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
paragonbioservices.com

See what CB Insights has to offer

Founded Year

1990

Stage

Acquired | Acquired

Total Raised

$22.4M

Valuation

$0000 

About Paragon Bioservices

Paragon Bioservices is a CRO-CMO whose focus is biopharmaceuticals including the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development, and cGMP manufacturing. Paragon's cGMP space includes microbial and mammalian suites, fill-finish and fully-segregated virus and BSL-3 facilities.

Paragon Bioservices Headquarter Location

801 West Baltimore Street Suite 401

Baltimore, Maryland, 21201,

United States

(800) 545-6569

Latest Paragon Bioservices News

Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth

Dec 9, 2021

Josh Sullivan Associate Editor Taipei’s Bo­ra Phar­ma­ceu­ti­cals has linked up with Taishin Health­care to in­vest about $108 mil­lion in­to CD­MOs and CROs in re­sponse to a boom­ing busi­ness en­vi­ron­ment for both in­dus­tries. The two com­pa­nies plan to en­ter the macro­mol­e­c­u­lar, and cell and gene ther­a­py man­u­fac­tur­ing spaces, and strength­en com­pet­i­tive­ness while bol­ster­ing Tai­wan’s CD­MO mar­ket. Ac­cord­ing to a re­port from Hart­ford, CT-based re­search group Glob­al In­for­ma­tion, the glob­al CD­MO mar­ket was val­ued at $160.1 bil­lion in 2020 and could grow to as much as $242.64 bil­lion by 2026. There are five CD­MOs in the world that have rev­enue above $500 mil­lion, while 75% of the field takes in less than $50 mil­lion in rev­enue, the re­port says. “In ad­di­tion to in­dus­try gi­ants that in­clude Lon­za, Catal­ent, WuXi Ad­vanced Ther­a­pies, Mi­naris Re­gen­er­a­tive Med­i­cine, and oth­ers, there are spe­cial­ty CD­MOs serv­ing the cell and gene ther­a­py mar­ket­place,” the re­port says. “For ex­am­ple, Fu­ji­film Cel­lu­lar Dy­nam­ics opened a $21M cGMP pro­duc­tion fa­cil­i­ty to sup­port its in­ter­nal cell ther­a­peu­tics pipeline, as well as serve as a CD­MO for iPS cell prod­ucts.” As a re­sult, CEO Bob­by Sheng and his team at Bo­ra will lean in­to M&A to quick­ly scale up ca­pac­i­ty. The com­pa­ny has com­plet­ed three deals in the past 10 years, and plans to sup­port com­pa­nies with promis­ing port­fo­lios. The re­port from GII points to “enor­mous” M&A deals with­in the cell and gene ther­a­py sec­tor, such as Ther­mo Fish­er Sci­en­tif­ic’s ac­qui­si­tion of Bram­mer Bio for $1.7 bil­lion, and Catal­ent’s grab of Paragon Bioser­vices for $1.2 bil­lion and MaS­Ther­Cell for $315 mil­lion. “In or­der to ef­fec­tive­ly al­lo­cate re­sources, in­ter­na­tion­al phar­ma­ceu­ti­cal mak­ers have moved to­wards spe­cial­iza­tion over the past few years, re­sult­ing in CD­MO ser­vices be­com­ing a trend sweep­ing the glob­al biotech phar­ma­ceu­ti­cal sec­tor,” Sheng said in a state­ment. Ed­i­tor’s Note: For more news and ex­clu­sive cov­er­age from the man­u­fac­tur­ing beat, sub­scribe to the End­points Man­u­fac­tur­ing week­ly re­port in your read­er pro­file. AUTHOR Josh Sullivan Associate Editor Just after Merck announced a deal to partner with a manufacturer to make its experimental Covid-19 pill molnupiravir in the US, the drugmaker has reached a similar partnership to make the pill for distribution throughout the rest of the world as well. Merck will partner with Thermo Fisher Scientific to manufacture the pill for Canada, the UK, several markets in the EU and Asia, as well as Latin America. The Whitby, Ontario site will be one of three in the world making the pill, which was developed with Ridgeback Biotherapeutics. Keep reading Endpoints with a free subscription Unlock this story instantly and join 125,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Josh Sullivan Associate Editor Covax, which ships Covid-19 vaccines to low- and middle-income nations, is calling for more Indian-made doses of AstraZeneca’s vaccine, Reuters reported, as a key manufacturer plans to halve the vaccine’s production temporarily until it gets more orders. The Serum Institute of India said uptake has slowed sharply and told an Indian television station that Covax was taking in fewer doses than offered. CEO Adar Poonawalla said uptake is expected to kick up next quarter, but a spokesperson for Gavi, which is providing low-cost shots worldwide as part of a collaboration with Covax, told Reuters the organization is still receiving “robust demand” for Covishield. Read More Patients prefer oral dosing, but swallowing tablets can be a challenge for many patients. The Zydis® orally disintegrating tablet (ODT) platform addresses challenges associated with oral dosing, expanding benefits for patients and options for healthcare providers. A strong growth trajectory is expected for ODTs given therapeutic innovation and continued technology development. Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing or sucking, offer a patient-friendly dosage form for the administration of small-molecule drugs, peptides and proteins. With the potential for multiple sites of drug absorption, often faster onset action for the active pharmaceutical ingredient (API), and potentially greater bioavailability, ODTs are an attractive option for drug developers considering first-to-market formulations or product line extensions of existing drugs with compatible API. In this report, we look at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients. Read the full sponsored article Please signup to continue — it's fast and free. This article is sponsored by Catalent and produced by Endpoints Studio. Read Article Senior Editor Each year, we aim to highlight 20 extraordinary women who are leaving their mark on drug R&D — and this year’s group was no exception. Our list, while by no means exhaustive, includes scientists, CEOs, researchers and professors who are supercharging the discovery and development of new therapies worldwide. Our team of writers spent time with each honoree (with a few exceptions), learning their stories and sketching profiles, which you’ll find in our special report. For the second time, we brought the celebration to a live virtual audience, featuring an award presentation followed by a panel on what it takes to break the glass ceiling in biopharma with Kojin Therapeutics CEO Luba Greenwood, AskBio CEO Sheila Mikhail, and Silverback Therapeutics CEO Laura Shawver. Our panelists had a lively discussion on how the industry’s culture has changed, how to handle sexual harassment, the progress we’ve made and the challenges that still hold women back today. We applaud each of our honorees for scaling the heights of biopharma R&D. You got to meet most of them via brief recordings we played during our live event. Below, you’ll find bonus videos offering a longer glimpse into those interviews. And if you didn’t get a chance to tune in to our main event live, you can replay the entire show. Premium subscription required Endpoints Staff Even though many biopharma leaders have come together in recent years to address its gender gap, the consensus is clear: We still have a long way to go. Companies this year were 2.5 times more likely than last year to have a diversity and inclusion program in place, according to a recent BIO survey, but women are still largely absent from executive roles. Getting women to enter the industry isn’t the problem — studies show that they represent just under half of all biotech employees around the world. But climbing through the ranks can be challenging, as women still report facing stereotypes, and, unfortunately, harassment. Keep reading Endpoints with a free subscription Unlock this story instantly and join 125,200+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Swedish venture capital manager Eir Ventures has rounded up a total of $138 million for its life sciences fund Eir Ventures I AB. The fund — launched just last year — is the firm’s first dedicated life sciences venture capital fund, according to a company statement. Backed by a syndicate of investors such as the European Investment Fund (EIF), Novo Holdings, and new blue-chip investors such as the Sustainable Development Umbrella Fund (SDUF), the fund claims to invest in life science companies “with products and technologies addressing significant unmet medical needs,” according to a company statement. Read More

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.